Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37686
Title: | Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial | Authors: | Ploumen, EH Buiten, RA Zocca, P Doggen, CJM Jessurun, GAJ Schotborgh, CE Roguin, A Danse, PW BENIT, Edouard Aminian, A Anthonio, RL Somi, S Linssen, GCM Hartmann, M Kok, MM von Birgelen, C |
Issue Date: | 2021 | Publisher: | WILEY | Source: | Catheterization and cardiovascular interventions, 98 (2) , p. E188 -E196 | Abstract: | Objectives To compare 2-year outcome following treatment with drug-eluting stents (DES) for acute myocardial infarction (MI) versus non-MI clinical syndromes. In acute MI patients, a stent-level comparison was performed, comparing Resolute Onyx versus Orsiro stents.Background In patients presenting with acute MI, higher adverse event rates have been reported. So far, no clinical results >1 year have been published of acute MI patients treated with Resolute Onyx.Methods This post-hoc analysis of the randomized BIONYX trial(NCT02508714) assessed the main outcome target vessel failure (TVF: cardiac death, target vessel MI, or target vessel revascularization) with Kaplan-Meier methods.Results Of all 2,488 trial participants, acute MI patients (n = 1,275[51.2%]) were significantly younger and had less comorbidities than non-MI patients (n = 1,213[48.8%]). TVF rates were lower in acute MI patients (77/1,275[6.1%] vs. 103/1,213[8.6%], HR:0.70, 95%-CI 0.52-0.94; p(log-rank) = 0.02), mainly driven by target vessel revascularization (4.1 vs. 6.1%, p(log-rank) = 0.03). Multivariate analysis showed no independent association of clinical syndrome with TVF (adjusted-HR: 0.81, 95%-CI 0.60-1.10; p = .17). In MI patients treated with Resolute Onyx (n = 626) versus Orsiro (n = 649), there was no difference in TVF (6.2 vs. 6.1%; p(log-rank) = 0.97) and its components. There was only 1(0.2%) definite-or-probable stent thrombosis in RO-ZES and 8(1.2%) in O-SES (p = .053).Conclusions Two years after treatment with thin-strut DES in this randomized trial, patients treated for acute MI had lower adverse event rates than non-MI patients. Yet, these findings were mainly attributable to between-group differences in patient and lesion characteristics. In patients who underwent PCI for acute MI, both Resolute Onyx and Orsiro showed favorable and similar 2-year outcomes. | Keywords: | clinical trials;drug‐eluting stent;myocardial infarction;percutaneous coronary intervention | Document URI: | http://hdl.handle.net/1942/37686 | ISSN: | 1522-1946 | e-ISSN: | 1522-726X | DOI: | 10.1002/ccd.29594 | ISI #: | 000627272100001 | Rights: | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Cathet Cardio Intervent - 2021 - Ploumen - Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents.pdf | Published version | 2.11 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.